The Shotlee Journal
Browse Shotlee articles about GLP-1 Medications.
Showing 9 / 934 GLP-1 Medications articles
Recent research highlights a potential safety concern with GLP-1 medications, linking them to an increased risk of dizziness and fainting, particularly in certain patient groups. Discover what this means for your health.
The booming popularity of GLP-1 medications for weight loss has coincided with a dramatic rise in telehealth services. This article delves into the benefits and significant risks of obtaining these powerful drugs online, highlighting critical safety concerns and offering guidance for patients.
The Food and Drug Administration (FDA) has issued a new warning regarding potential serious kidney complications associated with Alli, the sole over-the-counter weight loss medication available in the United States. The drug's label has been updated to reflect these risks, urging caution for consumers.
GLP-1 receptor agonists, known for their role in diabetes and weight management, are increasingly recognized for their broader health benefits, including effects on blood pressure. This article delves into how these medications work, their impact on cardiovascular health, and whether they are safe for individuals with hypertension.
A comprehensive guide to GLP-1 receptor agonists, understanding efficacy, managing side effects, and navigating the future of obesity treatment.
The GLP-1 revolution is just the beginning. This article delves into the cutting-edge advancements poised to reshape the future of weight loss and metabolic health, offering insights for patients and observers alike.
The revolutionary GLP-1 medications have transformed weight management, but the journey of innovation continues. Discover how upcoming drugs aim to enhance patient experience and outcomes.
Rhode Island's strategic health initiatives are commendable, but a recent budget proposal to cut Medicaid coverage for GLP-1 obesity treatments like Ozempic and Wegovy raises serious concerns. This decision, while seemingly a cost-saving measure, risks long-term health consequences and increased healthcare expenditures.
The FDA has issued a critical update to the drug facts label for Alli, the only over-the-counter weight loss medication available in the U.S. The changes highlight rare but potentially severe kidney-related side effects, prompting new warnings for consumers.
